Cortnum S, Sorensen P, et al: Neurosurgery 2010; 66 (May): 900-903 Newer CT scanners appear to have a higher sensitivity for identifying subarachnoid hemorrhage.
No Cerebrocervical Venous Congestion Found in MS
No Cerebrocervical Venous Congestion in Patients With Multiple Sclerosis. Doepp F, Paul F, et al: Ann Neurol 2010; 68 (August): 173-183 Cerebrospinal venous insufficiency and cerebral venous congestion do not appear to play a significant role in the pathogenesis of multiple sclerosis.
Background: Several recent studies have advanced the controversial notion that multiple sclerosis (MS) occurs in the context of chronic cerebrospinal venous insufficiency (CCSVI). Thus, internal jugular venous (IJV) stenosis promotes CCSVI with perivenular congestion of the brain, inflammation, and demyelination. That would explain the long known venocentric nature of MS plaques. Proposed criteria for diagnosing CCSVI include the demonstration of reflux of the deep cerebral veins and/or the internal jugular veins (IVJs) and vertebral veins (VVs), IJV stenosis, missing flow in IJVs and VVs, and inverse postural response of the cerebral venous drainage. Opening IVJ stenosis with stenting has reportedly improved some MS patients, and that has energized the MS population to seek out the procedure despite limited evidence for its efficacy. Most MS experts recommend that the provocative findings be confirmed before resorting to potentially dangerous endovascular manipulations. Objective: To determine if drainage of the cerebrospinal venous system in MS patients differs from controls. Methods: 56 MS patients and 20 controls were subjected to ultrasound examination. Extended extra-and transcranial color-coded sonography was used to characterize the extracranial venous blood volume flow (BVF), cross-sectional areas, IJV flow in supine and upright positions and during Valsalva maneuver (VM), and to examine if proposed CCSVI criteria were fulfilled uniquely in the MS group. Results: In all but 1 patient, the direction of blood flow was normal in the IJVs and VVs. IVJ stenosis was not detected in anyone. In both MS patients and controls, IJV and VV BVF were similar in the supine body position. On assuming an upright position, the decrease of total jugular BVF was less pronounced in MS patients (173 ±235 mL/min) than in controls (362 ±150 mL/min, P <0.001), and the cerebrocervical drainage for MS patients in the upright position was higher (318 ±242 mL/min) than in controls (123 ±109 mL/min; P <0.001). There were no differences between the 2 groups during Valsalva maneuver. Conclusions: Cerebrospinal venous drainage in MS patients does not differ from normal subjects except in the upright position, when cerebrospinal venous drainage in MS surpasses that of controls. To explain this finding, the authors suggest that vascular dysregulation occurs when MS affects the autonomic nervous system. Reviewer's Comments: In their discussion, the authors review the intracranial venous anatomy, emphasize the enormous capacity of extrajugular pathways for cerebral venous drainage, and explain why IVJ stenosis, even if present, should not result in CCSVI. As an example, most patients who lose one or both IVJs in radical neck dissection do not develop intracranial venous hypertension. And for the few that do, not one has been reported to develop MS. (Reviewer-Michael Jacewicz, MD). This work highlights the critical relay function of hippocampal CA1 neurons within a hippocampal-parietal network important to spatial memory tasks.
Lesions of CA1 Neurons in Hippocampus Lead to TGA
Background: Transient global amnesia (TGA) is characterized by sudden onset of a selective antegrade and retrograde amnesia without other neurological deficits, usually lasting 6 to 10 hours. Most patients experience a single episode. The pathology and pathophysiology of TGA have been poorly understood. It is known that hippocampal lesions in animals produce impairment in spatial memory. Objective: To investigate if spatial memory disruption due to hippocampal lesions underlies TGA in humans. Design: Case-controlled study. Participants: 6 men and 8 women (mean age, 67.8 ±7.6 years) presenting with an acute episode of TGA. They were compared to a control group of 10 healthy adults (5 men, 5 women; mean age, 67.0 ±7.1 years). Methods: All TGA subjects underwent brain MRI within 72 hours of symptom onset. TGA subjects and controls completed a virtual water maze test of spatial memory, with TGA subjects tested during the acute episode. TGA subjects also completed declarative verbal and visuoconstructive memory tests during the acute episode. Results: All TGA subjects were found to have hippocampal lesions selectively involving the CA1 sector (Sommer sector) on DWI and T2 MRI images within 48 to 72 hours after symptom onset. The lesion sizes ranged from 1 to 7 mm² (left, 4 mm²; right, 7 mm²; bilateral, 3 mm²). TGA subjects were found to have substantial deficits in both declarative verbal and visuoconstructive memory. Compared to controls, TGA subjects had profound deficits in completing the virtual water maze test. The degree of impairment on measures of verbal and spatial learning correlated with size of the hippocampal lesion on MRI and duration of the TGA episode. Conclusions: These findings show that acute and focal lesions of CA1 neurons in the human hippocampus lead to a profound impairment of place learning. TGA is a natural lesion model of disturbance of CA1 hippocampal neurons. Reviewer's Comments: This very elegant research provides a great deal of information about the site of transient pathology in TGA, and it also highlights the critical relay function of hippocampal CA1 neurons within this hippocampal-parietal network. The pathogenic mechanism of TGA remains unknown. Focal MR spectroscopy of lesions in TGA patients have revealed a lactate peak, suggesting that anaerobic glycolysis as a cellular stress response of CA1 neurons is the metabolic correlate of the diffusion changes seen in TGA. However, the pathogenic mechanism of this change remains elusive. (Reviewer-W. Steven Metzer, MD). In patients at high risk for cerebral ischemia, platelet aggregation may occur through cyclooxygenaseindependent mechanisms. In addition, platelet function assays are not ready for use in managing stroke patients taking ASA.
PFAs Not Ready for Managing Stroke Patients on ASA
Objective: To examine the evidence for and against the use of platelet function assays (PFA) to manage antiplatelet (AP) therapy in patients at high risk for cerebral ischemia. Design/Methods: This article and accompanying editorials were part of a published series called "Controversies in Stroke." The controversy was introduced with a case study (a patient with a recurrent lacunar infarct that occurred while taking 1 baby aspirin [ASA] daily), followed by questions (whether and how AP therapy should be altered, and whether PFA would be the useful in selecting further treatment). Results: A patient such as the hypothetical patient would be deemed an "ASA failure." It is first important to ensure that this "failure" is not the result of poor compliance or drug interactions impairing the AP effect of ASA. It may also be important to reconsider etiology of the stroke and rule out a non-atherothrombotic mechanism, if appropriate. These things having been done, a neurologist might be tempted to employ PFA as a guide to optimizing AP therapy. The first problem arises with the many definitions of "ASA resistance," based on aspects of the many different PFA systems. Among these are whether the assay used blood or platelet-rich plasma, what agonist/concentration was used to induce aggregation, and whether results from a single test or panel of tests were considered. Even after having discovered "ASA resistance" in vitro, there is nothing to guide clinicians concerning the next step. Adding clopidogrel to ASA or switching to clopidogrel would introduce a new set of problems: increased bleeding caused by dual AP therapy and/or the growing list of drug/genetic interactions with clopidogrel. Switching to ASA/extended-release dipyridamole would entail prescribing the very low dose of ASA in this combination. Increasing the ASA dose, presumably to the point where an AP effect was achieved, would entail the risk of increased side effects with the higher dose of ASA and perhaps concomitant decreased compliance. The proponent of using PFA to direct AP therapy after stroke stressed the high incidence of and poor outcomes associated with ASA resistance, yet acknowledged that the definition of ASA resistance varied and the lack of a validated approach to modifying AP therapy proven to improve outcomes in patients with ASA resistance. Conclusions: Both sides in the debate agree that ASA resistance is not all-or-nothing and that more study is needed. Reviewer's Comments: A further complicating point is that ASA may be doing what it is intended to do (fully inhibiting cyclooxygenase), yet platelet aggregation may still occur through cyclooxygenase-independent mechanisms, such as shear stress. Is this aspirin resistance? (Reviewer-James W. Schmidley, MD).
Paralytic Rabies May Mimic Guillain-Barre Syndrome

Rabies Viral Encephalitis: Clinical Determinants in Diagnosis With Special Reference to Paralytic Form.
Gadre G, Satishchandra P, et al: J Neurol Neurosurg Psychiatry 2010; 81 (July): [812] [813] [814] [815] [816] [817] [818] [819] [820] Paralytic rabies resembles Guillain-Barré syndrome but differs by including fever, fasciculations and paresthesias in the bitten limb, CSF pleocytosis, and eventually, a reduced level of consciousness.
Background: Rabies can begin with cerebral symptoms (encephalitic or furious rabies) or limb weakness (paralytic or dumb rabies). The encephalitic form includes limbic symptoms, hydrophobia, aerophobia, and inspiratory spasms, which are all well known phenomena that lead to the diagnosis. However, the paralytic form is harder to recognize because it resembles Guillain-Barré syndrome (GBS). Objective: To present the clinical features of paralytic rabies. Design: Retrospective study conducted at 2 neurology referral centers in India where rabies is endemic. Participants: 47 autopsy-confirmed cases of rabies, 13 with encephalitic onset and 34 with paralytic onset. Results: 34 of the 47 patients had a history of dog bite. The median incubation period between dog bite and symptom onset was 2 months (range, 1 week to 4 years). The median duration of illness from onset to death was 11 days (range, 2 days to 6 months). Prodromal symptoms consisted of fever (n=24) and headache (n=11). Among the patients with paralytic rabies, weakness began in 1 limb, usually the bitten limb (n=14), both limbs (n=14), or all limbs (n=6), and progressed rapidly. The authors did not report whether the weakness was upper or lower motor-neuron in type. "Bulbar involvement" (not further described) followed limb weakness within a week, and impaired consciousness followed within another. Nine of the 34 patients with paralytic rabies had paresthesias, 8 had fasciculations, 2 had hallucinations, and 5 had hydrophobia. Seventeen of them had CSF pleocytosis (median, 30 cells/mL; range, 8-770 cells/mL; predominantly lymphocytes), and 5 had albuminocytologic dissociation. Neutralizing antibody to rabies was found in the CSF of 40% of patients. Nuchal skin biopsy and corneal smear did not lead to the diagnosis because they were "not consistent." EMG and MRI were done on only 3 patients. Conclusions: Paralytic rabies resembles GBS but differs by including fever, fasciculations and paresthesias in the bitten limb, CSF pleocytosis, and eventually, a reduced level of consciousness. Unlike the encephalitic form, paralytic rabies is unlikely to present with hydrophobia. Reviewer's Comments: Especially in the United States where rabies infection is not endemic, paralytic rabies is a very difficult diagnosis to make because of the absence of classic features of encephalitic rabies, such as hydrophobia and inspiratory spasm, and the absence of a history of a dog bite, as seen in many patients in this series. (Reviewer-Marc D. Winkelman, MD).
Past Microbleeds, Hemorrhages Predict Recurrent ICH
Aspirin and Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.
Biffi A, Halpin A, et al: Neurology 2010; 75 (August 24): 693-698 In patients with cerebral amyloid angiopathy, recurrent lobar hemorrhage is predicted by past large lobar hemorrhages and microbleeds and hypodensity of cerebral white matter on CT scan.
Objective: To identify clinical and imaging predictors of recurrence of lobar intracerebral hemorrhage (ICH) caused by cerebral amyloid angiopathy (CAA). Design: Prospective longitudinal cohort study conducted at a single-center academic stroke program. Participants: All patients, aged ≥55 years who presented from 1994 to 2006 with symptomatic cerebral lobar ICH caused by CAA. The diagnosis of CAA was made when other causes of lobar ICH (coagulopathy, trauma, and vascular malformation) had been ruled out. Methods: Lobar microbleeds detected on gradient-echo MRI were defined as hemorrhages <5 mm in diameter. Hypodensity of cerebral white matter was assessed on CT scans. Results: The cohort contained 104 patients (age range, 64-80 years) who were followed up for a median of 3 years. There were 29 recurrent lobar ICHs, yielding a 2-year recurrence rate of 16%. In univariate analysis, significant predictors of recurrence were a lobar hemorrhage preceding the index hemorrhage (HR 9.8; 95% CI, 3.3-28.8; P<0.0001), the presence of cerebral white-matter hypodensity (HR 3.7; 95% CI, 1.3-11.1; P=0.01), posterior cerebral white-matter hypodensity (HR 5.7; 95% CI, 2.2-15.3; P=0.001), and the number of lobar microbleeds. For 2 to 4 microbleeds, the HR was 3.3 (95% CI, 1.1-1.4; P=0.03), and for ≥5 lobar microbleeds, the HR was 5.2 (95% CI, 2-14; P=0.001). In a multivariate Cox regression model controlled for lobar microbleed count, treatment with aspirin after the index event became a predictor for recurrent lobar ICH (HR 4; 95% CI 1.6-8.3; P=0.02). The magnitude of the effect of aspirin varied directly with the number of microbleeds: the HR was 1.9 for no microbleeds, and it rose to 5.3 for ≥5 microbleeds. Conclusions: In patients with CAA, recurrence of lobar ICH is common. Past large lobar ICHs and microbleeds and hypodensity of cerebral white matter on CT scan predict recurrent lobar ICH. The use of aspirin after a lobar ICH may also increase the risk of recurrence, especially in patients with numerous microbleeds. Reviewer's Comments: The data suggest that lobar microbleeds and white matter hypodensity are markers of the severity of CAA and, as the severity of CAA increases, aspirin becomes an increasingly more potent a promoter of lobar ICH. (Reviewer-Marc D. Winkelman, MD).
